YF
MCID: YLL002
MIFTS: 61

Yellow Fever (YF)

Categories: Infectious diseases, Liver diseases, Muscle diseases, Rare diseases, Skin diseases

Aliases & Classifications for Yellow Fever

MalaCards integrated aliases for Yellow Fever:

Name: Yellow Fever 12 73 20 58 54 3 44 15 70 32
Urban Yellow Fever 12 70 32
Sylvatic Yellow Fever 12 32
Jungle Yellow Fever 12 70
Yf 20 58
Yellow Fever, Sylvan 12
Bronze John 58
Yellow Jack 58

Characteristics:

Orphanet epidemiological data:

58
yellow fever
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Yellow Fever

CDC : 3 The yellow fever virus is found in tropical and subtropical areas of Africa and South America. The virus is spread to people by the bite of an infected mosquito. Yellow fever is a very rare cause of illness in U.S. travelers. Illness ranges from a fever with aches and pains to severe liver disease with bleeding and yellowing skin (jaundice). Yellow fever infection is diagnosed based on laboratory testing, a person's symptoms, and travel history. There is no medicine to treat or cure infection. To prevent getting sick from yellow fever, use insect repellent, wear long-sleeved shirts and long pants, and get vaccinated.

MalaCards based summary : Yellow Fever, also known as urban yellow fever, is related to west nile virus and plague. An important gene associated with Yellow Fever is EIF2AK4 (Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Sodium citrate and Orange have been mentioned in the context of this disorder. Affiliated tissues include t cells, heart and salivary gland, and related phenotypes are fever and headache

Disease Ontology : 12 A viral infectious disease that results in infection, has material basis in Yellow fever virus, which is transmitted by Aedes, transmitted by Haemagogus, or transmitted by Sabethes species of mosquitoes. The infection has symptom fever, has symptom muscle pain, has symptom backache, has symptom headache, has symptom shivers, has symptom loss of appetite, has symptom jaundice, and has symptom bleeding from the mouth, nose, eyes or stomach leading to vomitus containing blood.

Wikipedia : 73 Yellow fever is a viral disease of typically short duration. In most cases, symptoms include fever,... more...

Related Diseases for Yellow Fever

Diseases related to Yellow Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 530)
# Related Disease Score Top Affiliating Genes
1 west nile virus 31.9 RSAD2 OAS1 IL17A DDX58 CCR5
2 plague 31.6 IL6 IL1B DDX58 CCR5
3 meningoencephalitis 31.1 IL6 CXCL10 CCL5
4 vaccinia 30.9 STAT1 IRF7 IL6 IFNB1 CCR5
5 japanese encephalitis 30.9 STAT1 RSAD2 IFNB1 DDX58 CXCL10 CCL5
6 encephalitis 30.9 RSAD2 IL6 IL1B IFNB1 DDX58 CXCL10
7 disease by infectious agent 30.8 IL6 IL4 IL1B IL17A IFNB1 CCR5
8 tetanus 30.8 IL6 IL5 IL4 IL1B
9 chikungunya 30.8 STAT1 RSAD2 OAS1 IL6 IL1B DDX58
10 tick-borne encephalitis 30.8 RSAD2 OAS1 IFNB1 DDX58 CXCL10 CCR5
11 myelitis 30.7 IL6 IL17A IFNB1
12 pertussis 30.6 IL6 IL1B CCL5 CCL2
13 mumps 30.6 STAT1 IL6 IL1B IFNB1 CXCL10
14 measles 30.6 STAT1 OAS1 IRF7 IL6 IL1B IFNB1
15 west nile virus infection 30.6 OAS1 CCR5
16 rabies 30.5 STAT1 IRF7 DDX58 CXCL10 CCL5
17 dengue shock syndrome 30.5 IL6 IL1B CCL2
18 hemorrhagic disease 30.5 STAT1 IL6 IL5 IL4 IL1B IFNB1
19 dengue hemorrhagic fever 30.4 STAT1 IRF7 IL6 IL4 IFNB1 IFNAR1
20 rubella 30.4 IL6 IL5 IL4 IL1B IFNB1 DDX58
21 viral encephalitis 30.4 IL6 IL1B IFNB1 CXCL10 CCL5 CCL2
22 crimean-congo hemorrhagic fever 30.4 IL6 IFNB1 DDX58 CXCL10
23 leptospirosis 30.4 IL6 IL4 IL1B CCL2
24 herpes simplex 30.3 STAT1 OAS1 IRF7 IFNB1 DDX58 CCL5
25 b-cell growth factor 30.3 IL6 IL4
26 west nile fever 30.3 OAS1 CXCL10 CCR5
27 west nile encephalitis 30.3 OAS1 CCR5
28 venezuelan equine encephalitis 30.2 STAT1 IRF7 IFNB1 CXCL10 CCL2
29 toxic shock syndrome 30.2 IL6 IL4 IL1B
30 filariasis 30.2 IL6 IL5 CCL5
31 iridocyclitis 30.2 IL6 IL1B IL17A
32 optic neuritis 30.2 IL6 IL1B CXCL10 CCR5
33 mouth disease 30.1 STAT1 OAS1 IL6 DDX58
34 chickenpox 30.1 STAT1 IL6 IL4 IFNB1
35 bacterial pneumonia 30.0 IL6 IL1B IL17A
36 conjunctivitis 30.0 IL6 IL5 IL4 CCL2
37 kawasaki disease 30.0 IL6 IL4 IL1B IL17A CCL2
38 peritonitis 30.0 IL6 IL4 IL1B CCL2
39 hepatitis b 29.9 STAT1 IL6 IFNB1 IFNAR1
40 q fever 29.9 IL6 IL4 IL1B CCL5 CCL2
41 human immunodeficiency virus type 1 29.9 STAT1 CXCL10 CCR5 CCL5 CCL2
42 ulcerative colitis 29.9 IL6 IL4 IL1B IL17A
43 uveitis 29.9 IL6 IL4 IL1B IL17A CXCL10 CCR5
44 neuromyelitis optica 29.9 IL6 IL5 IL4 IL1B IL17A CXCL10
45 neuritis 29.9 IL6 IL4 IL1B CXCL10 CCR5 CCL5
46 diarrhea 29.8 STAT1 IL6 IL5 IL1B IFNB1
47 stomatitis 29.8 RSAD2 IL6 IL4 IL1B IFNB1 DDX58
48 colitis 29.8 IL6 IL4 IL1B IL17A CXCL10
49 spondyloarthropathy 29.8 IL6 IL4 IL1B IL17A CCL2
50 myocarditis 29.8 IL6 IL4 IL1B IL17A CCL2

Graphical network of the top 20 diseases related to Yellow Fever:



Diseases related to Yellow Fever

Symptoms & Phenotypes for Yellow Fever

Human phenotypes related to Yellow Fever:

58 31 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
2 headache 58 31 hallmark (90%) Very frequent (99-80%) HP:0002315
3 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
4 proteinuria 58 31 frequent (33%) Frequent (79-30%) HP:0000093
5 jaundice 58 31 frequent (33%) Frequent (79-30%) HP:0000952
6 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
7 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
8 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
9 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
10 gastrointestinal hemorrhage 58 31 frequent (33%) Frequent (79-30%) HP:0002239
11 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
12 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
13 oliguria 58 31 frequent (33%) Frequent (79-30%) HP:0100520
14 spontaneous abortion 58 31 frequent (33%) Frequent (79-30%) HP:0005268
15 menometrorrhagia 58 31 frequent (33%) Frequent (79-30%) HP:0400008
16 hypothermia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002045
17 hypotension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002615
18 encephalitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002383
19 nephropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0000112
20 photophobia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000613
21 dehydration 58 31 occasional (7.5%) Occasional (29-5%) HP:0001944
22 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
23 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
24 malignant hyperthermia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002047
25 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
26 meningitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001287
27 lethargy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001254
28 acute hepatic failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0006554
29 cardiorespiratory arrest 58 31 occasional (7.5%) Occasional (29-5%) HP:0006543

MGI Mouse Phenotypes related to Yellow Fever:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.2 CCL5 CCR5 CXCL10 DDX58 EIF2AK4 IFNAR1
2 homeostasis/metabolism MP:0005376 10.19 CCR5 CXCL10 DDX58 DNAJC14 EIF2AK4 IFNAR1
3 immune system MP:0005387 10.09 CCL2 CCL5 CCR5 CXCL10 DDX58 EIF2AK4
4 digestive/alimentary MP:0005381 9.97 CCR5 DDX58 IFNAR1 IL17A IL4 IL5
5 liver/biliary system MP:0005370 9.61 CCR5 DDX58 EIF2AK4 IFNAR1 IL4 IL5
6 neoplasm MP:0002006 9.23 CCR5 DDX58 IFNAR1 IFNB1 IL1B IL5

Drugs & Therapeutics for Yellow Fever

Drugs for Yellow Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2 Orange Approved Phase 4
3
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
4 Citrate Phase 4
5 Immunologic Factors Phase 4
6 Pharmaceutical Solutions Phase 4
7 Vaccines Phase 4
8
Lactitol Approved, Investigational Phase 3 585-86-4 157355
9
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4 445354
10 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
11 Nutrients Phase 3
12 Trace Elements Phase 3
13 retinol Phase 3
14 Retinol palmitate Phase 3
15 Micronutrients Phase 3
16 Vitamins Phase 3
17
tannic acid Approved Phase 1, Phase 2 1401-55-4
18
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
19
Metformin Approved Phase 2 657-24-9 4091 14219
20 Antibodies Phase 2
21 Immunoglobulins Phase 2
22 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
23 Anti-Inflammatory Agents Phase 2
24 Hypoglycemic Agents Phase 2
25
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
26
Aluminum sulfate Approved Phase 1 10043-01-3
27 Antibodies, Monoclonal Phase 1
28 Immunoglobulins, Intravenous Phase 1
29 gamma-Globulins Phase 1
30 Rho(D) Immune Globulin Phase 1
31 Antiviral Agents Phase 1
32
Methotrexate Approved 1959-05-2, 59-05-2 126941
33
BCG vaccine Approved, Investigational
34 Antibodies, Blocking

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old Unknown status NCT03725618 Phase 4
2 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina Completed NCT03368495 Phase 4
3 An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4
4 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
5 Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals Recruiting NCT03132311 Phase 4
6 A Randomized, Blinded Non-inferiority Trial on the Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines in Kenya and Uganda Active, not recruiting NCT02991495 Phase 4
7 Yellow Fever Vaccine Immunity After 1 Dose of Vaccine in Children and Adults: a Cohort Study in Non-endemic Area Active, not recruiting NCT02555072 Phase 4
8 Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination Active, not recruiting NCT04083430 Phase 4 Yellow Fever Vaccine
9 Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine Not yet recruiting NCT04059471 Phase 4
10 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3
11 The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient Completed NCT01426243 Phase 3
12 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
13 A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 Years in Non-Endemic Country(Ies) Completed NCT03342898 Phase 3 Placebo
14 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine. Completed NCT02699099 Phase 3
15 Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) Completed NCT01345240 Phase 3
16 Using Systems Vaccinology to Elucidate the Effects of Anti-inflammatory Therapy on Immune Response After Vaccination With a Live Attenuated Vaccine Completed NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
17 An Open-label Phase 2a Clinical Trial to Test the Effect of Yellow Fever Vaccination in a Background of Japanese Encephalitis Antibodies. Completed NCT01943305 Phase 2
18 Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants Completed NCT00436007 Phase 2
19 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2
20 Randomised, Double-blind, Phase II Evaluation of the Safety and Immunogenicity Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) Completed NCT00982137 Phase 2
21 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
22 Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
23 A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
24 The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Vaccination Recruiting NCT04269265 Phase 1, Phase 2
25 Safety, Tolerability, and Immunogenicity Dose-ranging Study of the Investigational Yellow Fever Vacine (vYF) Candidate Vaccine in Adults Recruiting NCT04142086 Phase 1, Phase 2
26 Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection (Part A) Recruiting NCT04267809 Phase 2 Metformin Hydrochloride
27 A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects Completed NCT02963909 Phase 1
28 Phase 1 First-in-Human, Time Lagged, Single Ascending Dose Study of TY014 in Healthy Adult Volunteers (Safety Arm - 1A) and Sequential Time Lagged, Parallel-Group, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study of TY014 in YF-17D Vaccine Strain-Challenged Healthy Adult Volunteers (Efficacy Arm - 1B) Completed NCT03776786 Phase 1
29 A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults Completed NCT02743455 Phase 1 ISA-720
30 Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability,and Immunogenicity of Graded Doses of XRX-001 Yellow Fever 17D, Inactivated Vaccine, Alum Adsorbed in Healthy Adults. Completed NCT00995865 Phase 1
31 Randomized Controlled Double-Blind Trial of the Comparative Viremia, Immunogenicity and Safety of a 17-D Live Attenuated Yellow Fever Vaccine (YF-VAX)Given Alone or in Combination With Human Immune Globulin (Gama STAN S/D) Completed NCT00254826 Phase 1
32 A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19 Recruiting NCT03891420 Phase 1 Galidesivir;Placebo
33 Yellow Fever Vaccination Under Low Dose Methotrexate Therapy - a Multi-Center Prospective Observational Controlled Pilot Study Unknown status NCT02383680
34 Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children Unknown status NCT02990182
35 Turnover of Antigen Specific Lymphocytes After Immunization With the 17D Yellow Fever Vaccine Unknown status NCT01290055
36 "Persistence of Neutralizing Antibodies After Immunization Against Yellow Fever (YF) in HIV-infected Patients: a Multicenter Study" Unknown status NCT03591003
37 Vaccines Immunogenicity in Children Transplanted or Candidate for a Renal, Hepatic, Cardiac or Pulmonary Transplantation, Followed in the Rhône-Alpes Region. A Descriptive and Prospective Monocentric Cohort Study Unknown status NCT03180359
38 A Clinical Study to Generate an Exploratory Training Set of Data Characterising Clinical Events, Physiological and Metabolic Responses, and Innate and Adaptive Immune Responses Following a Single Subcutaneous Immunisation With Either "Varilrix" Varicella-zoster Vaccine, "Stamaril" Yellow Fever Vaccine or Saline Placebo in Healthy Adults With Evidence of Pre-existing Immunity to Varicella-zoster and no Existing Immunity to Yellow Fever. Completed NCT01765413
39 Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military, Participants of "Dose-response Study of Yellow Fever Vaccine 17DD Produced by Bio-Manguinhos / Fiocruz" in 2009 Completed NCT03338231
40 Passive Enhanced Safety Surveillance of the Live Attenuated Yellow Fever Virus Vaccine Stamaril® in Korea Completed NCT03541694
41 Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults Completed NCT00616356
42 Duration of Immunity After Two Doses of Vaccine Against Yellow Fever in Adults Completed NCT02572518
43 Single Cell Transcriptomics for Characterizing the Human Immune Response to Yellow Fever Vaccination Completed NCT03458780 Yellow Fever Vaccine
44 The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination Completed NCT00708630
45 Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area Completed NCT03430388
46 Randomized Evaluation of a Conditional Cash Transfer Program for Routine Immunizations of Infants in Nigeria Completed NCT03870061
47 An Epidemiological Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children Completed NCT01391819
48 Duration of Immunity 10 Years After a Dose-response Study With Yellow Fever Vaccine - Complementary Study Recruiting NCT04416477
49 Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers Recruiting NCT03938597
50 Human Immune Responses to Yellow Fever Vaccination Active, not recruiting NCT00694655

Search NIH Clinical Center for Yellow Fever

Cochrane evidence based reviews: yellow fever

Genetic Tests for Yellow Fever

Anatomical Context for Yellow Fever

MalaCards organs/tissues related to Yellow Fever:

40
T Cells, Heart, Salivary Gland, Lymph Node, Brain, Bone Marrow, Eye

Publications for Yellow Fever

Articles related to Yellow Fever:

(show top 50) (show all 6220)
# Title Authors PMID Year
1
The structural determination of an insect sterol carrier protein-2 with a ligand-bound C16 fatty acid at 1.35-A resolution. 61 54
12855689 2003
2
Isolation and expression of a sterol carrier protein-2 gene from the yellow fever mosquito, Aedes aegypti. 54 61
12542635 2003
3
Neuromyelitis optica associated with yellow fever vaccination. 61
32524534 2021
4
Re-Analysis of 16S rRNA Gene Sequence Data Sets Uncovers Disparate Laboratory-Specific Microbiomes Associated with the Yellow Fever Mosquito (Aedes aegypti). 61
33797563 2021
5
Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. 61
33544838 2021
6
Structural and biochemical insights into flavivirus proteins. 61
33607183 2021
7
Live unattenuated vaccines for controlling viral diseases, including COVID-19. 61
32833258 2021
8
The influence of vector-borne disease on human history: socio-ecological mechanisms. 61
33501751 2021
9
The Costs of Contradictory Messages About Live Vaccines in Pregnancy. 61
33476239 2021
10
Ultrasound Findings and Laboratory Predictors of Early Mortality in Patients With Severe Yellow Fever. 61
33703928 2021
11
An updated and comprehensive review of the antiviral potential of essential oils and their chemical constituents with special focus on their mechanism of action against various influenza and coronaviruses. 61
33212200 2021
12
Assessment of immunity against Yellow Fever virus infections in northeastern Nigeria using three serological assays. 61
33783842 2021
13
Delay in health-seeking behaviour: Implication to yellow fever outcome in the 2019 outbreak in Nigeria. 61
33761167 2021
14
If I told you that there is no need for yellow fever vaccine booster would you still come to the travel clinic?: a cross-sectional study. 61
33712073 2021
15
The global burden of yellow fever. 61
33722340 2021
16
Potential autoimmune encephalitis following yellow fever vaccination: A report of three cases. 61
33780799 2021
17
Unique structural features of flaviviruses' capsid proteins: new insights on structure-function relationship. 61
33721656 2021
18
Differential effects of larval and adult nutrition on female survival, fecundity, and size of the yellow fever mosquito, Aedes aegypti. 61
33750400 2021
19
Travel restrictions as a disease control measure: Lessons from yellow fever. 61
32772788 2021
20
Fluorescent tagging the NS1 protein in yellow fever virus: Replication-capable viruses which produce the secretory GFP-NS1 fusion protein. 61
33388393 2021
21
Re-emergence of yellow fever in Venezuela: Report of the first case after 14 years. 61
33727174 2021
22
Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models. 61
33685778 2021
23
Oviposition behavior of wild yellow fever vector mosquitoes (Diptera: Culicidae) in an Atlantic Forest fragment, Rio de Janeiro state, Brazil. 61
33727688 2021
24
Incidence, Drivers and Global Health Implications of the 2019/2020 Yellow Fever Sporadic Outbreaks in Sub-Saharan Africa. 61
33739369 2021
25
Different Cross-Reactivities of IgM Responses in Dengue, Zika and Tick-Borne Encephalitis Virus Infections. 61
33807442 2021
26
Generation and Implementation of Reporter BHK-21 Cells for Live Imaging of Flavivirus Infection. 61
33796616 2021
27
Evaluation of kinase inhibitors as potential therapeutics for flavivirus infections. 61
33683474 2021
28
Efficiency of the CO2 -baited omni-directional Fay-Prince trap under semi-field conditions and characterizing response behaviours for the yellow fever mosquito, Aedes aegypti. 61
33780011 2021
29
Clustering based approach for population level identification of condition-associated T-cell receptor β-chain CDR3 sequences. 61
33765908 2021
30
Surveillance of the major pathogenic arboviruses of public health concern in Gabon, Central Africa: increased risk of West Nile virus and dengue virus infections. 61
33731022 2021
31
Performance of a sensitive haemozoin-based malaria diagnostic test validated for vivax malaria diagnosis in Brazilian Amazon. 61
33712019 2021
32
A Longitudinal Study Regarding the Health Profile of the 2017 South African Hajj Pilgrims. 61
33807142 2021
33
Single Cell Oil (SCO)-Based Bioactive Compounds: I-Enzymatic Synthesis of Fatty Acid Amides Using SCOs as Acyl Group Donors and Their Biological Activities. 61
33191449 2021
34
Is Dengue Vaccine Protection Possible? 61
33788926 2021
35
Mosquito-repellent controlled-release formulations for fighting infectious diseases. 61
33761967 2021
36
Argonaute-CLIP delineates versatile, functional RNAi networks in Aedes aegypti, a major vector of human viruses. 61
33794184 2021
37
A knockout screen of genes expressed specifically in Ae. aegypti pupae reveals a critical role for stretchin in mosquito flight. 61
33716097 2021
38
Systematic review: the impact of socioeconomic factors on Aedes aegypti mosquito distribution in the mainland United States. 61
32853170 2021
39
A machine-learning approach to map landscape connectivity in Aedes aegypti with genetic and environmental data. 61
33619083 2021
40
Infectious Diseases Seeker (IDS): An Innovative Tool for Prompt Identification of Infectious Diseases during Outbreaks. 61
33804605 2021
41
A first, naturally occurring substitution at the second pyrethroid receptor of voltage-gated sodium channel of Aedes aegypti. 61
33559956 2021
42
Impact of BCG revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the 'POPulation differences in VACcine responses' (POPVAC) programme. 61
33593770 2021
43
Understanding the role of arthropod vectors in the emergence and spread of plant, animal and human diseases. A chronicle of epidemics foretold in South of France. 61
33621458 2021
44
The long-run heterogeneous effects of a cholera pandemic on stature: Evidence from industrializing Japan. 61
33582501 2021
45
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. 61
33260195 2021
46
Safety and immunogenicity of 17DD attenuated yellow fever vaccine in howler monkeys (Alouatta spp.). 61
33219623 2021
47
Tolerance and humoral immune response to the yellow fever vaccine in sickle cell disease children treated with hydroxyurea: a multicentre prospective study. 61
33550421 2021
48
First-episode psychosis following vaccination against yellow fever: A case report. 61
33541715 2021
49
Assessing the impact of preventive mass vaccination campaigns on yellow fever outbreaks in Africa: A population-level self-controlled case series study. 61
33600451 2021
50
Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'POPulation differences in VACcine responses' (POPVAC) programme. 61
33593769 2021

Variations for Yellow Fever

Expression for Yellow Fever

Search GEO for disease gene expression data for Yellow Fever.

Pathways for Yellow Fever

Pathways related to Yellow Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 STAT1 RSAD2 OAS1 ISG20 IRF7 IL6
2
Show member pathways
13.87 STAT1 IL6 IL5 IL4 IL1B IL17A
3
Show member pathways
13.73 IL6 IL5 IL4 IL1B IL17A IFNB1
4
Show member pathways
13.6 STAT1 IL6 IL5 IL4 IL1B IL17A
5
Show member pathways
13.48 STAT1 IL6 IL5 IL4 IL1B IL17A
6
Show member pathways
13.37 IL6 IL5 IL4 IL1B IL17A CXCL10
7
Show member pathways
13.24 STAT1 RSAD2 OAS1 IRF7 IL6 IL1B
8
Show member pathways
13.04 STAT1 IRF7 IL6 IL1B IFNB1 IFNAR1
9
Show member pathways
12.91 STAT1 IL6 IL5 IL4 IL1B IL17A
10 12.85 STAT1 IL6 IL5 IL4 IFNAR1
11 12.84 STAT1 OAS1 IRF7 IL6 IL1B IFNB1
12
Show member pathways
12.75 STAT1 IRF7 IL6 IL1B IFNB1
13
Show member pathways
12.7 STAT1 IL6 IL5 IL4 IL1B IL17A
14
Show member pathways
12.67 STAT1 IL6 IL5 IL4 IL1B IL17A
15
Show member pathways
12.66 STAT1 RSAD2 OAS1 ISG20 IRF7 IL6
16
Show member pathways
12.65 IRF7 IL6 IL1B IFNB1 DDX58 CXCL10
17
Show member pathways
12.63 STAT1 IL6 IL1B IL17A CCL2
18
Show member pathways
12.62 STAT1 RSAD2 OAS1 ISG20 IRF7 IFNB1
19
Show member pathways
12.51 STAT1 IL6 IL5 IL4 IFNB1 IFNAR1
20 12.51 STAT1 RSAD2 OAS1 IRF7 IL4 IL1B
21
Show member pathways
12.48 STAT1 RSAD2 OAS1 IRF7 IL6 IL1B
22
Show member pathways
12.44 IL6 IL5 IL4 IL1B IL17A CXCL10
23
Show member pathways
12.41 IL6 CXCL10 CCR5 CCL5 CCL2
24
Show member pathways
12.4 IL6 IL4 IL1B CCL5 CCL2
25
Show member pathways
12.29 STAT1 IL4 IL1B CCR5
26
Show member pathways
12.29 STAT1 IL6 IL4 IL1B IFNB1 CXCL10
27 12.27 STAT1 IL6 IL1B IFNB1
28
Show member pathways
12.24 STAT1 IL1B IFNB1 IFNAR1
29 12.23 STAT1 OAS1 IRF7 IL6 IL1B IFNB1
30 12.14 IL6 IL1B IFNB1 CCL2
31
Show member pathways
12.14 STAT1 RSAD2 OAS1 ISG20 IRF7 IL6
32 12.12 IL6 IL4 IL1B CXCL10 CCL2
33 12.12 STAT1 IL6 IL4 IL1B IL17A CCL2
34 12.1 STAT1 IL1B IFNB1 IFNAR1
35 12.1 IL6 IL1B IFNB1 CXCL10 CCL5 CCL2
36
Show member pathways
12.04 STAT1 IL4 IL1B CCR5
37 12.01 IRF7 IL6 IL1B IFNB1
38 11.99 STAT1 IL6 IL1B CCL2
39 11.99 IL6 IL1B IL17A CCL5 CCL2
40 11.98 IL6 IL5 IL4 IL1B
41
Show member pathways
11.98 STAT1 IL6 IL4 IL1B IL17A
42 11.94 STAT1 IL6 IFNB1 IFNAR1
43 11.88 STAT1 IL6 IL5 IL4
44 11.87 IL5 IL4 IL1B IL17A
45
Show member pathways
11.84 STAT1 IL6 IL1B IL17A
46 11.78 IRF7 IL5 IFNB1
47 11.77 IL6 IL1B IFNB1
48 11.75 IL6 IL5 IL4 IL1B CCL5 CCL2
49 11.71 IL6 IL5 IL4
50 11.6 IL6 IL4 IL1B CXCL10 CCR5 CCL5

GO Terms for Yellow Fever

Cellular components related to Yellow Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 IL6 IL5 IL4 IL1B IL17A IFNB1
2 extracellular region GO:0005576 9.32 OAS1 IL6 IL5 IL4 IL1B IL17A

Biological processes related to Yellow Fever according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.3 STAT1 IL6 IL5 IL4 IL1B CXCL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 STAT1 IRF7 IL6 IL4 IL17A IFNB1
3 positive regulation of transcription, DNA-templated GO:0045893 10.13 STAT1 IRF7 IL6 IL5 IL4 IL1B
4 immune system process GO:0002376 10.11 RSAD2 OAS1 ISG20 IRF7 IL17A EIF2AK4
5 innate immune response GO:0045087 10.1 RSAD2 OAS1 ISG20 IRF7 IL17A DDX58
6 viral process GO:0016032 10.09 STAT1 RSAD2 IRF7 EIF2AK4 DDX58 CCR5
7 positive regulation of cell proliferation GO:0008284 10.09 STAT1 IL6 IL5 IL4 IL1B CXCL10
8 inflammatory response GO:0006954 10.01 IL6 IL5 IL1B IL17A CXCL10 CCR5
9 positive regulation of cell migration GO:0030335 9.99 IL4 IL1B CXCL10 CCL5
10 MAPK cascade GO:0000165 9.98 IL5 IL1B CCR5 CCL5 CCL2
11 immune response GO:0006955 9.97 IL6 IL5 IL4 IL1B IL17A CXCL10
12 chemotaxis GO:0006935 9.94 CXCL10 CCR5 CCL5 CCL2
13 cell-cell signaling GO:0007267 9.93 IL1B IL17A CXCL10 CCR5 CCL5
14 positive regulation of DNA-binding transcription factor activity GO:0051091 9.88 IL6 IL5 IL1B DDX58
15 positive regulation of tumor necrosis factor production GO:0032760 9.87 IL6 IL17A DDX58
16 cell chemotaxis GO:0060326 9.87 CCR5 CCL5 CCL2
17 cellular response to interleukin-1 GO:0071347 9.86 IL17A CCL5 CCL2
18 neutrophil chemotaxis GO:0030593 9.85 CXCL10 CCL5 CCL2
19 regulation of insulin secretion GO:0050796 9.85 IL6 IL1B CCL5
20 interferon-gamma-mediated signaling pathway GO:0060333 9.85 STAT1 OAS1 IRF7
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IL6 IL4 CCL5
22 cellular response to lipopolysaccharide GO:0071222 9.85 IL6 IL1B CXCL10 CCR5 CCL2
23 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 STAT1 IL6 CCL5
24 positive regulation of interleukin-8 production GO:0032757 9.83 IL6 IL1B DDX58
25 positive regulation of interleukin-6 production GO:0032755 9.83 IL6 IL1B IL17A DDX58
26 humoral immune response GO:0006959 9.82 IL6 IFNB1 CCL2
27 monocyte chemotaxis GO:0002548 9.81 IL6 CCL5 CCL2
28 chemokine-mediated signaling pathway GO:0070098 9.81 CXCL10 CCR5 CCL5 CCL2
29 response to virus GO:0009615 9.81 RSAD2 OAS1 ISG20 IRF7 IFNB1 IFNAR1
30 protein kinase B signaling GO:0043491 9.8 IL1B CCL5 CCL2
31 cellular response to organic cyclic compound GO:0071407 9.8 STAT1 IL1B CCL5 CCL2
32 type I interferon signaling pathway GO:0060337 9.8 STAT1 RSAD2 OAS1 ISG20 IRF7 IFNB1
33 positive regulation of JAK-STAT cascade GO:0046427 9.78 IL6 IL5 CCL5
34 positive regulation of T cell proliferation GO:0042102 9.78 IL6 IL4 IL1B CCL5
35 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 IL1B CCL5 CCL2
36 JAK-STAT cascade GO:0007259 9.77 STAT1 IFNAR1 CCL2
37 negative regulation of viral genome replication GO:0045071 9.77 RSAD2 OAS1 ISG20 IFNB1 CCL5
38 positive regulation of defense response to virus by host GO:0002230 9.73 STAT1 IL4 EIF2AK4 DDX58
39 positive regulation of interferon-alpha production GO:0032727 9.72 STAT1 IRF7 DDX58
40 cellular response to interferon-alpha GO:0035457 9.7 OAS1 IFNAR1
41 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.7 IL1B DDX58
42 positive regulation of neuroinflammatory response GO:0150078 9.69 IL6 IL1B
43 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.66 RSAD2 IL6
44 vascular endothelial growth factor production GO:0010573 9.66 IL6 IL1B
45 defense response to virus GO:0051607 9.65 STAT1 RSAD2 OAS1 ISG20 IRF7 IL6
46 cytokine-mediated signaling pathway GO:0019221 9.4 STAT1 IL6 IL5 IL4 IL1B IL17A

Molecular functions related to Yellow Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.28 IL6 IL5 IL4 IL1B IL17A IFNB1
2 CCR5 chemokine receptor binding GO:0031730 9.16 STAT1 CCL5
3 chemokine activity GO:0008009 9.13 CXCL10 CCL5 CCL2

Sources for Yellow Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....